Keyphrases
Population-based Study
100%
Young children
50%
Relapsed or Refractory Acute Myeloid Leukemia
50%
Infant Patients
50%
Gemtuzumab Ozogamicin
50%
Vidaza
50%
Young Adolescents
50%
Azacitidine
50%
Pediatric Patients
50%
Netherlands
50%
Population-based Cohort Study
50%
Sex-related
50%
Group Studies
50%
Juvenile Myelomonocytic Leukemia
50%
Phase II Study
50%
Glioma Subtypes
50%
Preadolescent children
50%
Pediatric Glioma
50%
Survival Disparities
50%
Myelodysplastic Syndrome
50%
Survival Rate
50%
Central Nervous System Tumors
50%
Malignant Tumor
41%
Pilocytic Astrocytoma
33%
Survival Outcomes
33%
Neutralizing Effect
25%
Incidence Characteristics
25%
Diffuse Glioma
25%
Age Groups
25%
Tumor Characteristics
25%
Survival Characteristics
25%
Sex Differences
25%
Aging Characteristics
25%
Survival Gap
25%
High Risk
25%
Treatment Characteristics
25%
Acute Lymphoblastic Leukemia
20%
Minimal Residual Disease
20%
Confidence Interval
20%
Observed Survival
16%
Non-malignant Tumor
16%
Overall Survival
15%
CD22
10%
Complete Remission
10%
Venous Disease
10%
Infant Acute Lymphoblastic Leukemia
10%
Relapsed Disease
10%
Working Diagnosis
10%
Second Allogeneic Stem Cell Transplantation
10%
Pharmacokinetics
10%
Medicine and Dentistry
Azacitidine
50%
Survival Rate
50%
Toddlers
50%
Inotuzumab Ozogamicin
50%
Central Nervous System Tumor
50%
Myelodysplastic Syndrome
50%
Juvenile Myelomonocytic Leukemia
50%
Acute Lymphoblastic Leukemia
50%
Pediatrics Patient
50%
Adolescence
50%
Malignant Neoplasm
41%
Pilocytic Astrocytoma
33%
Hematopoietic Stem Cell Transplantation
20%
Minimal Residual Disease
20%
Neoplasm
16%
Disease
15%
Overall Survival
15%
Vein Occlusion
10%
Transplantation
10%
Allograft
10%
Pharmacokinetics
10%
Optic Nerve Tumor
8%
Deterioration
8%
Tumor of Central Nervous System
8%
Diagnosis
8%
Pediatrics
8%
Mortality Rate
8%
Cancer Registry
8%
Recommended Drug Dose
5%
Adverse Event
5%
Bone Marrow Toxicity
5%
Hematologic Malignancy
5%
Clinical Trial
5%
Pharmacology, Toxicology and Pharmaceutical Science
Central Nervous System Tumor
50%
Inotuzumab Ozogamicin
50%
Myelodysplastic Syndrome
50%
Azacitidine
50%
Acute Lymphoblastic Leukemia
50%
Juvenile Myelomonocytic Leukemia
50%
Survival Rate
50%
Malignant Neoplasm
35%
Pilocytic Astrocytoma
28%
Minimal Residual Disease
20%
Disease
15%
Overall Survival
15%
Neoplasm
14%
Remission
10%
Vein Occlusion
10%
Pharmacokinetics
10%
Deterioration
7%
Optic Nerve Tumor
7%
Mortality Rate
7%
Cancer Registry
7%
Adverse Event
5%
Hematologic Malignancy
5%
Bone Marrow Toxicity
5%
Clinical Trial
5%
